Page 301 - Haematologica Vol. 109 - July 2024

LETTER TO THE EDITOR
References
1. Buitenkamp TD, Izraeli S, Zimmermann M, et al. Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group. Blood. 2014;123(1):70-77.
2. Ceppi F, Stephens D, den Hollander BS, et al. Clinical presentation and risk factors of serious infections in children with Down syndrome treated for acute lymphoblastic leukemia. Pediatr Blood Cancer. 2016;63(11):1949-1953.
3. Rabin KR, Devidas M, Chen Z, et al. Outcomes in children, adolescents, and young adults with Down syndrome and ALL: a report from the Children’s Oncology Group. J Clin Oncol. 2024;42(2):218-227.
4. Meyr F, Escherich G, Mann G, et al. Outcomes of treatment for relapsed acute lymphoblastic leukaemia in children with Down syndrome. Br J Haematol. 2013;162(1):98-106.
5. Rafei H, Kantarjian HM, Jabbour EJ. Targeted therapy paves the way for the cure of acute lymphoblastic leukaemia. Br J Haematol. 2020;188(2):207-223.
6. Laurent AP, Siret A, Ignacimouttou C, et al. Constitutive activation of RAS/MAPK pathway cooperates with trisomy 21 and is therapeutically exploitable in Down syndrome B-cell leukemia. Clin Cancer Res. 2020;26(13):3307-3318.
7. Lane AA, Chapuy B, Lin CY, et al. Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation. Nat Genet. 2014;46(6):618-623.
8. Bhansali RS, Rammohan M, Lee P, et al. DYRK1A regulates B cell acute lymphoblastic leukemia through phosphorylation of
FOXO1 and STAT3. J Clin Invest. 2021;131(1):e135937.
9. Page EC, Heatley SL, Eadie LN, et al. HMGN1 plays a significant role in CRLF2 driven Down Syndrome leukemia and provides a
potential therapeutic target in this high-risk cohort. Oncogene.
2022;41(6):797-808.
10. Li Z, Chang TC, Junco JJ, et al. Genomic landscape of Down
syndrome-associated acute lymphoblastic leukemia. Blood.
2023;142(2):172-184.
11. O’Doherty A, Ruf S, Mulligan C, et al. An aneuploid mouse strain
carrying human chromosome 21 with Down syndrome
phenotypes. Science. 2005;309(5743):2033-2037.
12. Tahtouh T, Durieu E, Villiers B, et al. Structure-activity
relationship in the Leucettine family of kinase inhibitors. J Med
Chem. 2022;65(2):1396-1417.
13. Lindberg MF, Deau E, Miege F, et al. Chemical, biochemical,
cellular, and physiological characterization of Leucettinib-21, a Down syndrome and Alzheimer’s disease drug candidate. J Med Chem. 2023;66(23):15648-15670.
14. Zhou Q, Phoa AF, Abbassi RH, et al. Structural optimization and pharmacological evaluation of inhibitors targeting dual- specificity tyrosine phosphorylation-regulated kinases (DYRK) and CDC-like kinases (CLK) in glioblastoma. J Med Chem. 2017;60(5):2052-2070.
15. Laetsch TW, Maude SL, Balduzzi A, et al. Tisagenlecleucel in pediatric and young adult patients with Down syndrome- associated relapsed/refractory acute lymphoblastic leukemia. Leukemia. 2022;36(6):1508-1515.
Haematologica | 109 July 2024
2315